Alobaid, S.M.; Alshahrani, R.M.; Alonazi, A.S.; Alrasheed, N.M.; Alamin, M.A.; Alshammari, T.K.; Bin Dayel, A.F.; Elnagar, D.M.; Alotaibi, R.R.; Almuthnabi, L.A.;
et al. Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. Pharmaceuticals 2024, 17, 374.
https://doi.org/10.3390/ph17030374
AMA Style
Alobaid SM, Alshahrani RM, Alonazi AS, Alrasheed NM, Alamin MA, Alshammari TK, Bin Dayel AF, Elnagar DM, Alotaibi RR, Almuthnabi LA,
et al. Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. Pharmaceuticals. 2024; 17(3):374.
https://doi.org/10.3390/ph17030374
Chicago/Turabian Style
Alobaid, Shatha M., Rahaf M. Alshahrani, Asma S. Alonazi, Nawal M. Alrasheed, Maha A. Alamin, Tahani K. Alshammari, Anfal F. Bin Dayel, Doaa M. Elnagar, Rana R. Alotaibi, Lama A. Almuthnabi,
and et al. 2024. "Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus" Pharmaceuticals 17, no. 3: 374.
https://doi.org/10.3390/ph17030374
APA Style
Alobaid, S. M., Alshahrani, R. M., Alonazi, A. S., Alrasheed, N. M., Alamin, M. A., Alshammari, T. K., Bin Dayel, A. F., Elnagar, D. M., Alotaibi, R. R., Almuthnabi, L. A., Almasud, D. H., Al-Ammar, S. E., Almadhi, S. O., Almalke, R. A., Aldamri, N. T., Alghibiwi, H. K., Alkhelb, D. A., & Alrasheed, N. M.
(2024). Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus. Pharmaceuticals, 17(3), 374.
https://doi.org/10.3390/ph17030374
